Clinical oncology最新文献

{"title":"Enhancing Treatment Resilience in Palliative Oesophagogastric Cancer: Nutritional, Access, and Scoring Considerations","authors":"M. Wajid Siddique , M.A. Cheema","doi":"10.1016/j.clon.2025.103985","DOIUrl":"10.1016/j.clon.2025.103985","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"49 ","pages":"Article 103985"},"PeriodicalIF":3.0,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145741228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reflections on “Radiating Excellence: A Decade of Pioneering Radiotherapy Trials and Collaborative Leadership at Leeds Cancer Research UK Clinical Trials Unit”","authors":"U. Yaseen","doi":"10.1016/j.clon.2025.103987","DOIUrl":"10.1016/j.clon.2025.103987","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"49 ","pages":"Article 103987"},"PeriodicalIF":3.0,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145793407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CAR-T in Central Nervous System Tumours: Promising Science, Slow Clinical Progress","authors":"M. Mehfooz, H. Raza, A. Javed, Y. Ejaz","doi":"10.1016/j.clon.2025.103986","DOIUrl":"10.1016/j.clon.2025.103986","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"49 ","pages":"Article 103986"},"PeriodicalIF":3.0,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145827034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate Cancer: Artificial Intelligence Advancements in Diagnosis and Early Detection","authors":"A. Shahzad, M. Waqar, T. Imran, M. Faisal","doi":"10.1016/j.clon.2025.103984","DOIUrl":"10.1016/j.clon.2025.103984","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"49 ","pages":"Article 103984"},"PeriodicalIF":3.0,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145741183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemoradiotherapy for Oesophageal Adenocarcinoma: The Debate is Not Over","authors":"M. Guardascione , L. Foltran , F. Puglisi","doi":"10.1016/j.clon.2025.103982","DOIUrl":"10.1016/j.clon.2025.103982","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"50 ","pages":"Article 103982"},"PeriodicalIF":3.0,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145908802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RCR Meetings","authors":"","doi":"10.1016/S0936-6555(25)00229-8","DOIUrl":"10.1016/S0936-6555(25)00229-8","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"48 ","pages":"Article 103974"},"PeriodicalIF":3.0,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145568838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing Real-Time Digital Quality Assurance in Multimodality Oesophagogastric Cancer Trials","authors":"M.W. Siddique , M.A. Cheema","doi":"10.1016/j.clon.2025.103983","DOIUrl":"10.1016/j.clon.2025.103983","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"49 ","pages":"Article 103983"},"PeriodicalIF":3.0,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145741157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Avoiding Adjuvant Prophylactic Neck Irradiation in Lateralized Oral Cavity Cancer (APRON)","authors":"S. Sinha ,&nbsp;S. Ghosh Laskar ,&nbsp;S. Dhingra ,&nbsp;A. Kumar ,&nbsp;S. Mohanty ,&nbsp;A. Budrukkar ,&nbsp;M. Swain ,&nbsp;P.N. Bishnu ,&nbsp;I. Joy ,&nbsp;R. Ali ,&nbsp;S. Kannan ,&nbsp;N. Mummudi","doi":"10.1016/j.clon.2025.103980","DOIUrl":"10.1016/j.clon.2025.103980","url":null,"abstract":"<div><div>Oral cavity squamous cell carcinoma (OCSCC) is the second most common cancer in India with an age standardised ratio of 10.3 per 100,000 (both sexes combined) (1). Most patients (60%-80%) present in advanced stages with a high risk of nodal involvement. The current standard of care involves surgery followed by adjuvant radiotherapy (RT), often including elective nodal irradiation (ENI) even in pathologically node-negative patients. However, recent evidence suggests that well-selected patients with adequate surgical clearance may be adequately treated with limited volumes of ENI, potentially sparing them unnecessary toxicity.</div><div>The APRON study is a single-arm, phase II trial evaluating whether limiting ENI is non-inferior to standard adjuvant RT in carefully selected patients with lateralized oral cavity cancers. Eligible patients are adults with biopsy-proven squamous cell carcinoma of the bucco-alveolar region or oral tongue who have undergone margin-negative resection and adequate elective nodal dissection (≥18 nodes). Only well-lateralized tumours (≥1 cm from midline for tongue cancers) are included. The primary endpoint is regional control at 2 years, defined as any nodal recurrence (ipsilateral or contralateral). Secondary endpoints include swallowing function (MD Anderson Dysphagia Inventory; modified barium swallow), local and regional recurrence-free survival, disease-free and overall survival, acute/chronic toxicity, quality of life, salvage rates for recurrence, and dosimetry comparisons. The study also assesses the safety and efficacy of moderate hypofractionation (50 Gy/20 fractions) in the adjuvant setting.</div><div>A sample size of 106 patients is planned, with early stopping rules for safety. Statistical analysis will use the Clopper–Pearson method for nodal failure rates and propensity score matching with historical controls for non-inferiority testing. By limiting ENI in well-selected patients, APRON aims to reduce treatment-related morbidity while maintaining oncologic efficacy, potentially improving functional outcomes and preserving regional immune function. The study is expected to provide valuable evidence for de-escalated adjuvant strategies in OCSCC management.</div></div><div><h3>CTRI Number</h3><div>CTRI/2025/03/082341.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"49 ","pages":"Article 103980"},"PeriodicalIF":3.0,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145721382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liquid Biopsy: A Gentler Window Into Paediatric Brain Tumours","authors":"H. Raza,&nbsp;M. Mehfooz,&nbsp;A. Javed,&nbsp;Y. Ejaz","doi":"10.1016/j.clon.2025.103979","DOIUrl":"10.1016/j.clon.2025.103979","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"49 ","pages":"Article 103979"},"PeriodicalIF":3.0,"publicationDate":"2025-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145687098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Geriatric Oncology in Italy. Where we are. A CIPOMO (Italian College of Primary Hospital Medical Oncologists)-Gioger (Italian Group of Geriatric Oncology) Survey","authors":"S. Barni ,&nbsp;A. Luciani ,&nbsp;P. Tralongo ,&nbsp;L. Cavanna ,&nbsp;G. Aprile ,&nbsp;S. Leo ,&nbsp;C. Aschele ,&nbsp;M. Giordano ,&nbsp;R.R. Silva ,&nbsp;C. Ortega ,&nbsp;M.G. Sarobba ,&nbsp;F. Artioli ,&nbsp;A. Scanni ,&nbsp;L. Fioretto","doi":"10.1016/j.clon.2025.103965","DOIUrl":"10.1016/j.clon.2025.103965","url":null,"abstract":"<div><h3><em>Aims</em></h3><div>By the year 2040, the population of adult individuals aged 65 years and older is expected to reach 44%. Understanding the impending global demographic change is important for all stakeholders along the oncology pathway.</div></div><div><h3><em>Materials and</em> <em>methods</em></h3><div>CIPOMO (Italian College of Primary Hospital Medical Oncologists) with Gioger (Italian Group of Geriatric Oncology) conducted a survey by sending a questionnaire to the directors of oncology departments to get a picture of the situation and to be able to devise plans to improve care, fill gaps in research, education, and implementation, in essence to undertake major health care management changes. The questionnaire included eight questions: the presence and type of figures dedicated to geriatric oncology, the presence of a geriatrics department, the use of a geriatric assessment, which one is used and when it is performed, when a patient is geriatric, and whether there are clinical trials reserved for the elderly population.</div></div><div><h3><em>Results</em></h3><div>A total of 159 questionnaires were sent and 144 responses were obtained, with a response rate of 90.5%. The analysis shows that in less than 38.97% of hospitals there are figures dedicated to geriatric oncology; when these figures are present in 80.65% are oncologist, 62.9% geriatrician, and 22.58% nurses. Regarding the minimum age to consider an elderly patient, 44.85% set the limit at 70 years and 47.06% at 75 years. Eighty percent state that a geriatric assessment is performed in their wards, the G8 questionnaire is used by 65.77%, the multidimensional geriatric assessment by 29.73%, and 1.8% use the <strong>erythrocyte sedimentation rate (</strong>ESR-13) or other instruments. Regarding when the geriatric assessment is done, in 40.44% it is done at the first access to oncology, in 16.91% ‘on demand’, in 15.44% in cases of deciding on medical treatment, and in 13.24% at first access and periodically afterwards. The presence in hospital of a geriatrics department is 44.85% and 25.74% the availability of a geriatrician; in 30%, no specific figure is available. When asked about the availability of clinical trials specific to the elderly population, in 87.5% the answer is negative.</div></div><div><h3><em>Conclusion</em></h3><div>The results show the shortage of professionals trained or assigned to geriatric oncology (including oncologists, geriatricians, nurses, or other dedicated staff), a growing but still insufficient specific cultural preparation, and as is known, very few clinical trials dedicated to elderly oncology patients.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"49 ","pages":"Article 103965"},"PeriodicalIF":3.0,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145660216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}